First-in-class biopharmaceutical for treating osteoarthritis

Levicept is developing a biological fusion protein, p75NTR-Fc, comprising the endogenous human neurotrophin receptor and an immunoglobulin Fc fragment, for treating chronic pain in patients with osteoarthritis.